References
- Rhodes B. A., Zamora P. A., Newell K. D., Valdez E. F. Tc-99m-labelling of murine monoclonal antibody fragments. J Nucl Med 1986; 27: 685–93
- Lanteiegne D., Hnatowich D. J. The labelling of DTPA coupled proteins with Tc-99m. Int J Appl Radiol Biol 1984; 35: 617–21
- Mather S. J., Ellison D. Reduction medicated Tc-99m labelling of monoclonal antibodies. J Nucl Med 1990; 31: 692–7
- Fritzberg A. R., Abrams P. G., Beaumier P. L., et al. Specific and subtle labelling of antibodies with Technetium-99m with a diamide dithiolate chelating agent. Proc Natl Acad Sci USA 1988; 85: 4025–9
- Solanki K., Gill R., Stoker M. A case for automated radiopharmaceutical dispensing. Nucl Med Commun 1993; 14: 282
- Granowska M., Britton I. C. E., Mather S. J., et al. Radioimmunoscintigraphy with Technetium-99m monoclonal antibody, SM3, in gynaecological cancer. Eur J Nucl Med 1993; 20: 483–9
- Lo Buglio A. F., Wheeler R. H., Trang S, et al. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci USA 1989; 86: 4220–4
- Granowska M., Mather S. J., Britton K. E. 99MTechnetium-labelled antibodies for radioimmunoscintigraphy. Monoclonal antibodies 2, A. A. Epenetos. Chapman and Hall, London 1993; 375–82
- Britton K. E. Radiobiology workshop-an elemental dose approach to radioimmunotherapy. Monoclonal antibodies 2, A. A. Epenetos. Chapman and Hall, London 1993; 383–90
- Beierwaltes W. H. The treatment of thyroid carcinoma with radioactive iodine. Semin Nucl Med 1976; 8: 79–94
- Hird V., Maraveyas A., Snook D., et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993; 68: 403–6
- Oehr P., Wagner V., Briele B., et al. Improved survival of patients with advanced ovarian cancer after repeated im-munoscintigraphy and induction of anti idiotypic antibodies. J Nucl Med 1991; 32: 1051
- Britton K. E., Mather S. J., Granowska M. Radiolabeled monoclonal antibodies in oncology III radioimmunotherapy. Nucl Med Commun 1991; 12: 333–47
- Rao D. V., Howell R. W. Time dose fractionation in radioimmunotherapy: implication for selecting radionuclides. J Nucl Med 1993; 34: 1801–10
- Howell R. W., Goddu S. M., Rao D. V. Application of the linear-quadratic model to radioimmunotherapy: further support for the advantage of longer-lived radionuclides. J Nucl Med 1994; 35: 1861–9
- Foxwell B. M. J., Band H. A., Long J., et al. Conjunction of monoclonal antibodies to a synthetic peptide substitute for protein kinase: a method of labelling antibodies with 32-P. Br J Cancer 1988; 57: 489–503
- Britton K. E., Band H. A., Creighton A. M., et al. Radioimmunotherapy, RIT, with 32-P labelled antibodies, a preliminary report. Eur J Nucl Med 1994; 21: 783
- Band H., Creighton A. M., Britton K. E., et al. 32P-labelled antibodies for radioimmunotherapy: a review of recent developments and preliminary report of the first phase I studies. Tumour Targeting 1995; 1: 1–8
- Rosier H., Noelpp U., Baluenstein P. Endoarterial radionuclide embolising tumour therapy. Radionuclides for therapy, P. A. Schubiger, P. H. Haslar. Proc 4th Bottstein Colloquium, Weirenlingen, Roche, Basle 1986; 227–44
- Holliger P., Prosperio T., Winter G. 'Diabodies': small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90: 6444–8
- Paganelli G., Magnani P., Zito F., et al. Three step monoclonal antibody tumour targetting in carcinoembryonic positive patients. Cancer Res 1991; 51: 5960–6